方盛制药：公司年报点评：归核发展成效显著，创新研发稳步推进

Ping Peng p.peng@htisec.com 点评： | --- | --- | --- | --- | --- | --- | |----------------------|--------|--------|-------|-------|-------| | [Table_FinanceInfo] | 2022 | 2023 | 2024E | 2025E | 2026E | | 营业收入（百万元） | 1792 | 1629 | 1751 | 2058 | 2396 | | (+/-)YoY(%) | 14.4% | -9.1% | 7.5% | 17.5% | 16.4% | | 净利润（百万元） | 286 | 187 | 233 | 298 | 368 | | (+/-)YoY(%) | 308.1% | -34.6% | 24.8% | 28.0% | 23.5% | | 全面摊薄 EPS( 元 ) | 0.65 | 0.42 | 0.53 | 0.68 | 0.84 | | 毛利率 (%) | 67.3% | 68.1% | 68.7% | 69.2% | 69.6% | | 净 ...